on Onco-Innovations Limited (CVE:ONCO)
Onco-Innovations Welcomes Dr. Dennis Hall to Advisory Board
Onco-Innovations Limited, a company specializing in cancer research and treatment, has appointed Dr. Dennis Hall to its Scientific and Clinical Advisory Board. Dr. Hall, a Professor of Chemistry at the University of Alberta, is renowned for his contributions to organoboron chemistry and drug discovery. He holds the Tier 1 Canada Research Chair in Boron Chemistry and has over 175 peer-reviewed publications.
Dr. Hall will guide Onco-Innovations in research and development, particularly in advancing the Polynucleotide Kinase 3 Phosphatase (PNKP) Inhibitor Technology. CEO Thomas O'Shaughnessy highlights Dr. Hall's alignment with the company's mission to develop precision therapies for solid tumors.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Onco-Innovations Limited news